Eisai Inc. today announced updated results of ENHANCE 1, a Phase 1b/2 trial investigating eribulin mesylate (marketed as HALAVEN®, "eribulin"), in combination with the Merck & Co., Inc.,...

Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the presentation of new preclinical data for its novel oral...

Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that the one-year efficacy and safety results from its FIT Phase 3 clinical program of fostamatinib for chronic or persistent immune...

As an Advanced Consulting Partner within the Amazon Web Services (AWS) Partner Network (APN) and the official AWS Networking Sponsor for AWS re:Invent 2017, CenturyLink, Inc. (NYSE: CTL) deployed...

GES (Global Education Summit) 2017 Future Education Conference was held in Beijing on November 28-29, 2017. The participants of the conference included leading characters of Chinese education...